生命科学资讯

Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD

Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking

Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

FDA issues safety alert on Trividia blood glucose monitors

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials

Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail

MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody

Assessing Myelin Formation and Therapeutic Response Using 3D Organoids

iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004

Supreme Court steps in: Trump's emergency tariffs struck down

Ionis scraps early candidate for Alzheimer’s in people with Down syndrome

Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint

Mainz Biomed looks to shed ColoAlert, shifts focus in US

Chutes & Ladders—Roche taps Aussie oncologist to lead early research

Biohaven charts comeback path after FDA blow, placing bets on obesity

Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch

Daiichi picks former Novartis CMO John Tsai to head up R&D